Article
Recommendations on data sharing in HIV drug resistance research.
PLoS medicine - 1 Sept 2023
Inzaule Seth C, Siedner Mark J, Little Susan J, Avila-Rios Santiago, Ayitewala Alisen, Bosch Ronald J, Calvez Vincent, Ceccherini-Silberstein Francesca, Charpentier Charlotte, Descamps Diane, Eshleman Susan H, Fokam Joseph, Frenkel Lisa M, Gupta Ravindra K, Ioannidis John P A, Kaleebu Pontiano, Kantor Rami, Kassaye Seble G, Kosakovsky Pond Sergei L, Kouamou Vinie, Kouyos Roger D, Kuritzkes Daniel R, Lessells Richard, Marcelin Anne-Genevieve, Mbuagbaw Lawrence, Minalga Brian, Ndembi Nicaise, Neher Richard A, Paredes Roger, Pillay Deenan, Raizes Elliot G, Rhee Soo-Yon, Richman Douglas D, Ruxrungtham Kiat, Sabeti Pardis C, Schapiro Jonathan M, Sirivichayakul Sunee, Steegen Kim, Sugiura Wataru, van Zyl Gert U, Vandamme Anne-Mieke, Wensing Annemarie M J, Wertheim Joel O, Gunthard Huldrych F, Jordan Michael R, Shafer Robert W
Abstract excerpt
• Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that may be less effective, less well-tolerated, and more expensive than those used in first-line regimens. • HIV drug resistance studies are designed to determine which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.